Quarter
Charts

Immunic, Inc.

IMUX

CIK 0001280776 · Quarterly mode · latest period FY2014 (Q1) (ending 2014-03-31) · sourced from SEC EDGAR

At a glance · FY2014 (Q1)

Revenue
$22K
Gross Profit
$9K

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
2/100
  • Profitability
    0ROIC -1387.4% (10% = solid, 20%+ = moat)
  • Liquidity
    12Current Ratio 0.75 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Insufficient data
  • Growth
    0Insufficient data
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$161K
investment in PP&E
Stock-based comp (TTM)
$9M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$24M
everything owned
Total liabilities
$31M
everything owed
Stockholders' equity
$-7M
shareholder claim

Recent performance · 53 quarters

Revenue
$22K
Net Income↓-5.0% -$1M
$-26M
Free Cash Flow↓-266.7% -$8K
$-11K
Operating Margin
-53981.8%

Drill down

IMUX Sankey

See Immunic, Inc.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

IMUX Charts

53 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

IMUX Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics